Brighton Jones LLC Grows Stake in Eli Lilly and Company $LLY

Brighton Jones LLC grew its holdings in Eli Lilly and Company (NYSE:LLY) by 4.5% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 10,888 shares of the company’s stock after acquiring an additional 467 shares during the quarter. Brighton Jones LLC’s holdings in Eli Lilly and Company were worth $8,488,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. WestEnd Advisors LLC increased its holdings in shares of Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after acquiring an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC purchased a new position in shares of Eli Lilly and Company in the 1st quarter valued at about $27,000. Citizens National Bank Trust Department increased its holdings in shares of Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after acquiring an additional 27 shares during the last quarter. Blume Capital Management Inc. increased its holdings in shares of Eli Lilly and Company by 46.7% in the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after acquiring an additional 14 shares during the last quarter. Finally, IMG Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company in the 2nd quarter valued at about $35,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.6%

Eli Lilly and Company stock opened at $825.86 on Friday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $935.63. The stock has a 50 day moving average of $768.01 and a two-hundred day moving average of $768.44. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a market capitalization of $781.65 billion, a price-to-earnings ratio of 53.98, a PEG ratio of 1.19 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period last year, the firm earned $3.92 EPS. The firm’s revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on LLY shares. Cantor Fitzgerald set a $925.00 price target on Eli Lilly and Company and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Morgan Stanley dropped their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a research note on Friday, October 3rd. Deutsche Bank Aktiengesellschaft dropped their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. Guggenheim restated a “buy” rating and set a $948.00 price target on shares of Eli Lilly and Company in a research note on Thursday, October 16th. Finally, JPMorgan Chase & Co. dropped their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $938.61.

Insider Activity at Eli Lilly and Company

In related news, Director J Erik Fyrwald acquired 1,565 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director owned 74,578 shares of the company’s stock, valued at $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Daniel Skovronsky acquired 1,000 shares of the firm’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the transaction, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. This trade represents a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 4,514 shares of company stock worth $2,894,841 in the last ninety days. Company insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.